Drugs / vvDD-hIL-2-RG-1
vvDD-hIL-2-RG-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07001592 | May 2025 → Apr 2028 expected | colorectal cancer, esophageal cancer, gastric adenocarcinoma, liver cancer +2 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vvDD-hIL-2-RG-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07001592 ↗ |
| Known as | vvDD-hIL2 | “This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in...” NCT07001592 ↗ |
| Known as | vvDD-IL-2 | “The vvDD-IL-2 virus was designed to activate T-cells with a goal to reduce systemic toxicity while optimizing immune clearance of tumors following intraperitoneal delivery.” NCT07001592 ↗ |
| Action | Activate | “The vvDD-IL-2 virus was designed to activate T-cells” NCT07001592 ↗ |
| Route | Other | “administered via intra-tumoral (IT) injection” NCT07001592 ↗ |